WebDec 10, 2024 · Sanofi has put the focus on oncology, with 28 candidates in the pipeline, followed by 18 for immuno-inflammation. Synthorx brings to Sanofi its lead … WebDec 13, 2024 · The addition of THOR-707 and Synthorx’s other earlier-stage cytokine programmes to Sanofi’s pipeline will enhance Sanofi’s position in oncology and in immuno-oncology, the company said.. Synthorx’s Expanded Genetic Alphabet platform is expected to be a source for developing a differentiated therapeutic pipeline.
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
WebAug 9, 2024 · One variant, termed THOR-707, ... Synthorx, a Sanofi Company, Inc. holds patents related to both the technology and pegylated IL-2 molecules presented herein, on … WebNov 9, 2024 · THOR-707, SAR444245: IL-2 mutein with P65 replaced by an azide-containing non-natural amino acid, ... (41, 42), CT-ID: NCT04009681: Sanofi: Results: Six phase 1 to 2 … papiercorso appingedam
Sanofi beat out 3 suitors and one last-minute bid in its pricey …
WebIn Cynomolgus monkey, subcutaneous dosing of THOR-809 demonstrated dose-dependent proliferation and activation of peripheral Tregs with no detectable proliferation of Teffs or … WebAccueil / Essais cliniques / Etude de phase 2 multicentrique, non randomisée, en ouvert, à plusieurs cohortes évaluant le bénéfice clinique du SAR444245 (THOR-707) associé à d’autres thérapies anticancéreuses pour le traitement de patients atteints de cancer du poumon ou de mésothéliome pleural. WebOct 29, 2024 · THOR-707 is currently being evaluated by Sanofi in an ongoing Phase 1 open-label, multi-center, dose escalation and expansion trial. This study is designed to evaluate … papier copic